What is Cerecin?
Cerecin operates as a multifaceted healthcare enterprise dedicated to addressing the complexities of brain health. With nearly two decades of industry leadership, the firm specializes in the development of evidence-based solutions that span pharmaceuticals, medical foods, diagnostics, and advanced medical devices. Their market position is defined by a commitment to innovation, targeting a broad spectrum of conditions ranging from mild memory impairment to severe, life-altering neurological diseases. By integrating e-health products into their clinical offerings, Cerecin bridges the gap between traditional medical intervention and modern digital health, providing a comprehensive ecosystem for patient care and neurological management.
How much funding has Cerecin raised?
Cerecin has raised a total of $233.9M across 10 funding rounds:
Series B
$7.5M
Series C
$35M
Private Equity
$26.1M
Series A
$12M
Private Equity
$9.5M
Series D
$11M
Debt
$3.9M
Debt
$4.9M
Private Equity
$84.1M
Other Financing Round
$40M
Series B (2006): $7.5M, investors not publicly disclosed
Series C (2008): $35M, investors not publicly disclosed
Private Equity (2008): $26.1M, investors not publicly disclosed
Series A (2009): $12M, investors not publicly disclosed
Private Equity (2010): $9.5M, investors not publicly disclosed
Series D (2010): $11M, investors not publicly disclosed
Debt (2011): $3.9M, investors not publicly disclosed
Debt (2012): $4.9M, investors not publicly disclosed
Private Equity (2012): $84.1M featuring Inventages Venture Capital Investment Inc.
Other Financing Round (2021): $40M backed by Hana Financial Investment Co. and S&K Security Group
Key Investors in Cerecin
Inventages Venture Capital Investment Inc.
A premier venture capital firm focused on life-sciences, nutrition, and wellness, providing strategic guidance and financial support to high-growth healthcare companies.
Hana Financial Investment Co.
A comprehensive financial services provider offering asset management and advisory services to institutional and individual clients seeking innovative investment opportunities.
S&K Security Group
A specialized technology firm focused on critical infrastructure and surveillance, bringing a unique operational perspective to their investment portfolio.
What's next for Cerecin?
Looking ahead, the recent capital influx provides Cerecin with the necessary liquidity to advance its clinical trials and expand its commercial footprint in the global neurological market. The strategic focus will likely shift toward scaling the distribution of its medical foods and diagnostic tools, while simultaneously pushing forward with its pharmaceutical pipeline. As the company matures, the emphasis on high-impact neurological research will remain the primary driver of its growth strategy. Investors and stakeholders are closely monitoring the firm's ability to translate its robust research foundation into scalable, market-ready products that address the growing global demand for effective brain health interventions.
See full Cerecin company page
